A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Condition:   Erosive Esophagitis Interventions:   Drug: BLI5100;   Drug: PPI Control Sponsor:   Braintree Laboratories Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials